

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

Abattis Biologix Corporation  
Suite 310 - 885 Dunsmuir Street  
Vancouver BC V6C 1N5

Phone: 778-908-6650 Fax: 604-538-6658

**Item 2. Date of Material Change**

June 11, 2012

**Item 3. News Release**

A News Release dated and issued June 11, 2012 at Vancouver, British Columbia, through Stockwatch and SEDAR.

**Item 4. Summary of Material Change**

See news release, a copy of which is attached hereto.

**Item 5. Full Description of Material Change**

See news release, a copy of which is attached hereto.

**Item 6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

Not applicable.

**Item 8. Executive Officer**

Mike Withrow, President & CEO  
Telephone: 778-908-6650

**Item 9. Date of Report**

June 11, 2012

Suite 310 – 885 Dunsmuir St  
Vancouver, BC V6C 1N5  
Tel: 778-908-6650  
Fax: 604-538-6658



### **Abattis Announces Consulting Agreement with Wakabayashi Fund, LLC**

VANCOUVER, BRITISH COLUMBIA – Abattis Biologix Corporation (“**Abattis**” or the “**Company**”) is pleased to announce that it has entered into a consulting agreement (the “**Agreement**”) with Wakabayashi Fund, LLC (“**Wakabayashi**”) of Japan, to provide capital funding and capital consulting services to the Company. The Agreement is for a term of six months.

For the services being provided to Abattis, Wakabayashi will receive a cash fee equal to 7% of all capital raised for the Company by Wakabayashi, and will be issued an aggregate of 3,000,000 common shares of Abattis (the “**Shares**”), of which 1,500,000 Shares are issuable on signing of the Agreement, with the remaining 1,500,000 Shares being issuable on August 4, 2012.

All Shares issued to Wakabayashi will be subject to a Canadian hold period expiring four months and one day after the issuance of the Shares.

"We are pleased to have engaged the team at Wakabayashi and look forward to working with them to further fund our existing and near term commercialization efforts", stated Mike Withrow, President and CEO of Abattis.

#### **About Wakabayashi Fund LLC.**

Wakabayashi Fund LLC., a private equity fund with offices in Tokyo, Japan and New York, NY, provides corporate capitalization and institutional investor relations consulting services. Wakabayashi Fund may invest on a principal basis and acts in an agency capacity to procure capital for both profitable and emerging small-cap companies, identifying institutional funding sources for its clients and further develops the investor relations activities.

#### **About Abattis Biologix Corporation**

Abattis Biologix Corporation is a specialty bio-technology life sciences company that has acquired intellectual property, conducts research, and works to develop proprietary health and wellness solutions that address chronic illnesses and disease in animals and humans through proprietary and patent pending formulations. The company has identified targeted channels to market and license proprietary patent pending products throughout the world.

ON BEHALF OF THE COMPANY

“Mike Withrow”

Mike Withrow  
Director

#### **For information please contact:**

##### **Hamza Thindal Capital Corp.**

P: 888.371.9098

E: [info@htcapitalcorp.com](mailto:info@htcapitalcorp.com)

[www.htcapitalcorp.com](http://www.htcapitalcorp.com)

Neither the CNSX Exchange nor its regulations services accepts responsibility for the adequacy or accuracy of this release.